Efficacy and safety of micafungin, an echinocandin antifungal agent, on invasive fungal infections in patients with hematological disorders

被引:33
作者
Tamura, Kazuo [1 ]
Urabe, Akio [2 ]
Yoshida, Minoru [3 ]
Kanamaru, Akihisa [4 ]
Kodera, Yoshihisa [5 ]
Okamoto, Shinichiro [6 ]
Maesaki, Shigefumi [7 ]
Masaoka, Tohru [8 ]
机构
[1] Fukuoka Univ, Sch Med, Dept Internal Med, Jonan Ku, Fukuoka 8140180, Japan
[2] Kanto Med Ctr NTT EC, Ctr Prevent Med, Shinagawa Ku, Tokyo, Japan
[3] Teikyo Univ, Sch Med, Mizonokuchi Hosp, Dept Internal Med 4,Takatsu Ku, Kawawsaki, Japan
[4] Kinki Univ, Sch Med, Dept Hematol, Ohno Higashi, Osakasayama, Japan
[5] Japan Red Cross Nagoya First Hosp, Dept Hematol, Nakamura Ku, Nagoya, Aichi, Japan
[6] Keio Univ, Sch Med, Dept Internal Med, Div Hematol, Tokyo, Japan
[7] Saitama Med Univ Hosp, Dept Infect Dis & Infect Control, Iruma, Saitama, Japan
[8] Osaka Med Ctr Canc & Cardiovasc Dis, Higashinari Ku, Osaka, Japan
关键词
Micafungin; echinocandin; fungal infection; febrile neutropenia; empirical therapy; hematological disorders; LIPOSOMAL AMPHOTERICIN-B; FEBRILE NEUTROPENIC PATIENTS; STEM-CELL TRANSPLANTATION; PERSISTENT FEVER; EMPIRICAL THERAPY; DOUBLE-BLIND; OPEN-LABEL; FK463; VORICONAZOLE; CASPOFUNGIN;
D O I
10.1080/10428190802635500
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The study was conducted as a prospective multicenter trial to evaluate the efficacy and safety of micafungin in patients with invasive fungal infections (IFIs) in hematological disorders. A total of 277 patients was registered, and 197 were assessed for clinical efficacy. The mean dosage and duration of micafungin were 170.7mg/day and 22.0 days, respectively. The efficacy rates were 87.5% (7/8) for patients with candidiasis, 44.7% (17/38) for probable IFIs, 61.9% (39/63) for possible IFIs and 80.7% (71/88) for those who failed to respond to antibacterials. In patients with febrile neutropenia (below 500L), despite broad-spectrum antibacterial treatment over 2 days, 86.3% (44/51) of patients had a favourable response to micafungin. The incidence of adverse events related to micafungin was 14.1% (39/277), but most of them were mild and reversible. These data indicate the usefulness of micafungin as a novel therapeutic drug for both empirical and targeted therapy for IFIs.
引用
收藏
页码:92 / 100
页数:9
相关论文
共 29 条
[1]   Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy - A randomized, controlled trial [J].
Boogaerts, M ;
Winston, DJ ;
Bow, EJ ;
Garber, G ;
Reboli, AC ;
Schwarer, AP ;
Novitzky, N ;
Boehme, A ;
Chwetzoff, E ;
De Beule, K .
ANNALS OF INTERNAL MEDICINE, 2001, 135 (06) :412-422
[2]   Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group [J].
De Pauw, Ben ;
Walsh, Thomas J. ;
Donnelly, J. Peter ;
Stevens, David A. ;
Edwards, John E. ;
Calandra, Thierry ;
Pappas, Peter G. ;
Maertens, Johan ;
Lortholary, Olivier ;
Kauffman, Carol A. ;
Denning, David W. ;
Patterson, Thomas F. ;
Maschmeyer, Georg ;
Bille, Jacques ;
Dismukes, William E. ;
Herbrecht, Raoul ;
Hope, William W. ;
Kibbler, Christopher C. ;
Kullberg, Bart Jan ;
Marr, Kieren A. ;
Munoz, Patricia ;
Odds, Frank C. ;
Perfect, John R. ;
Restrepo, Angela ;
Ruhnke, Markus ;
Segal, Brahm H. ;
Sobel, Jack D. ;
Sorrell, Tania C. ;
Viscoli, Claudio ;
Wingard, John R. ;
Zaoutis, Theoklis ;
Bennett, John E. .
CLINICAL INFECTIOUS DISEASES, 2008, 46 (12) :1813-1821
[3]   A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis [J].
de Wet, NTE ;
Bester, AJ ;
Viljoen, JJ ;
Filho, F ;
Suleiman, JM ;
Ticona, E ;
Llanos, EA ;
Fisco, C ;
Lau, W ;
Buell, D .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2005, 21 (07) :899-907
[4]   Micafungin (FK463), alone or in combination with other systemic antifungal agents, for the treatment of acute invasive aspergillosis [J].
Denning, David W. ;
Marr, Kieren A. ;
Lau, Wendi M. ;
Facklam, David P. ;
Ratanatharathorn, Voravit ;
Becker, Cornelia ;
Ullmann, Andrew J. ;
Seibel, Nita L. ;
Flynn, Patricia M. ;
van Burik, Jo-Anne H. ;
Buell, Donald N. ;
Patterson, Thomas F. .
JOURNAL OF INFECTION, 2006, 53 (05) :337-349
[5]   Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation [J].
Hashino, Satoshi ;
Morita, Lena ;
Takahata, Mutsumi ;
Onozawa, Masahiro ;
Nakagawa, Masao ;
Kawamura, Takahito ;
Fujisawa, Fumie ;
Kahata, Kaoru ;
Izumiyama, Koh ;
Yonezumi, Masakatsu ;
Chiba, Koji ;
Kondo, Takeshi ;
Asaka, Masahiro .
INTERNATIONAL JOURNAL OF HEMATOLOGY, 2008, 87 (01) :91-97
[6]   Antifungal mechanism of FK463 against Candida albicans and Aspergillus fumigatus [J].
Hatano, K ;
Morishita, Y ;
Nakai, T ;
Ikeda, F .
JOURNAL OF ANTIBIOTICS, 2002, 55 (02) :219-222
[7]   Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis [J].
Herbrecht, R ;
Denning, DW ;
Patterson, TF ;
Bennett, JE ;
Greene, RE ;
Oestmann, JW ;
Kern, WV ;
Marr, KA ;
Ribaud, P ;
Lortholary, O ;
Sylvester, R ;
Rubin, RH ;
Wingard, JR ;
Stark, P ;
Durand, C ;
Caillot, D ;
Thiel, E ;
Chandrasekar, PH ;
Hodges, MR ;
Schlamm, HT ;
Troke, PF ;
de Pauw, B .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (06) :408-415
[8]   Role of micafungin in the antifungal armamentarium [J].
Ikeda, Fumiaki ;
Tanaka, Shigeki ;
Ohki, Hidenori ;
Matsumoto, Satoru ;
Maki, Katsuyuki ;
Katashima, Masataka ;
Barrett, David ;
Aoki, Yoshiyasu .
CURRENT MEDICINAL CHEMISTRY, 2007, 14 (11) :1263-1275
[9]  
Ishikawa T, 2006, JPN J CHEMOTHER, V54, P125
[10]  
Karthaus M, 2002, NEW ENGL J MED, V347, P2080